These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 23027412)
21. Relationship of affect recognition with psychopathology and cognitive performance in schizophrenia. Bozikas VP; Kosmidis MH; Anezoulaki D; Giannakou M; Karavatos A J Int Neuropsychol Soc; 2004 Jul; 10(4):549-58. PubMed ID: 15327733 [TBL] [Abstract][Full Text] [Related]
22. [Cognitive remediation and cognitive assistive technologies in schizophrenia]. Sablier J; Stip E; Franck N Encephale; 2009 Apr; 35(2):160-7. PubMed ID: 19393385 [TBL] [Abstract][Full Text] [Related]
23. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia. AhnAllen CG Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029 [TBL] [Abstract][Full Text] [Related]
24. Antipsychotic treatment in schizophrenia: the role of computerized neuropsychological assessment. Kertzman S; Reznik I; Grinspan H; Weizman A; Kotler M Isr J Psychiatry Relat Sci; 2008; 45(2):114-20. PubMed ID: 18982837 [TBL] [Abstract][Full Text] [Related]
25. Cognitive impairment of executive function as a core symptom of schizophrenia. Wobrock T; Ecker UK; Scherk H; Schneider-Axmann T; Falkai P; Gruber O World J Biol Psychiatry; 2009; 10(4 Pt 2):442-51. PubMed ID: 18609418 [TBL] [Abstract][Full Text] [Related]
26. Control of attention in schizophrenia. Birkett P; Brindley A; Norman P; Harrison G; Baddeley A J Psychiatr Res; 2006 Oct; 40(7):579-88. PubMed ID: 16359710 [TBL] [Abstract][Full Text] [Related]
33. Assessment of cognitive functions in animal models of schizophrenia. Nikiforuk A Pharmacol Rep; 2018 Aug; 70(4):639-649. PubMed ID: 29894866 [TBL] [Abstract][Full Text] [Related]
34. Stimulating the development of drug treatments to improve cognition in schizophrenia. Green MF Annu Rev Clin Psychol; 2007; 3():159-80. PubMed ID: 17716052 [TBL] [Abstract][Full Text] [Related]
36. Schizophrenia: treatment targets beyond monoamine systems. Ibrahim HM; Tamminga CA Annu Rev Pharmacol Toxicol; 2011; 51():189-209. PubMed ID: 20868275 [TBL] [Abstract][Full Text] [Related]
37. Behavioral animal models of antipsychotic drug actions. Peleg-Raibstein D; Feldon J; Meyer U Handb Exp Pharmacol; 2012; (212):361-406. PubMed ID: 23129339 [TBL] [Abstract][Full Text] [Related]
38. Developing treatments for cognitive deficits in schizophrenia: the challenge of translation. Young JW; Geyer MA J Psychopharmacol; 2015 Feb; 29(2):178-96. PubMed ID: 25516372 [TBL] [Abstract][Full Text] [Related]
39. Animal models of working memory: a review of tasks that might be used in screening drug treatments for the memory impairments found in schizophrenia. Dudchenko PA; Talpos J; Young J; Baxter MG Neurosci Biobehav Rev; 2013 Nov; 37(9 Pt B):2111-24. PubMed ID: 22464948 [TBL] [Abstract][Full Text] [Related]
40. The attentional set-shifting test paradigm in rats for the screening of novel pro-cognitive compounds with relevance for cognitive deficits in schizophrenia. Denis Goetghebeur PJ; Dias R Curr Pharm Des; 2014; 20(31):5060-8. PubMed ID: 24345267 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]